Metastatic Breast Cancer Survey - Kisqali (ribociclib)

Rethink Breast Cancer is looking for woman with HR-positive, HER2-negative advanced or metastatic breast cancer and women who have been treated with Kisqali (ribociclib) to talk about their experience.

The pan-Canadian Oncology Drug Review (pCODR) makes recommendations about whether provincial health plans should pay for new cancer drugs. pCODR will soon be reviewing the use of Kisqali (ribociclib) to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process. We would like to speak with women about their experience with HR-positive, HER2-negative advanced or metastatic breast cancer.
 
You do not need to live in Canada to respond to this survey; we appreciate input from every patient.

We are also interested in speaking directly with women who have treatment experience with Kisqali (ribociclib).

Please contact Shawna Rich-Ginsberg at shawna@rethinkbreastcancer.com if you would be willing to participate in a brief telephone interview.
 
We would like to thank everyone for helping to ensure that patient experiences are represented in the cancer drug funding review process.
 
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.

Question Title

* 1. Have you been diagnosed with HR-positive, HER2-negative advanced or metastatic breast cancer?

Question Title

* 3. When diagnosed, were you premenopausal or postmenopausal?

Question Title

* 4. Have you experienced any symptoms as a result of your breast cancer? (If you can, please try to focus on symptoms caused by the cancer rather than by any treatments.)

Question Title

* 5. What treatment phase are you in?

Question Title

* 6. What treatments have you received since your diagnosis?

Question Title

* 7. Please describe your overall experience with these cancer treatments including both positive and negative experiences.

Question Title

* 8. What side effects have you experienced as a result of treatment?

Question Title

* 9. If you experienced treatment side effects, which did you find most difficult to tolerate?

Question Title

* 10. Have you had difficulties accessing cancer treatments?

Question Title

* 11. Do you have financial challenges as a result of your breast cancer treatment?

Question Title

* 12. Have you needed financial assistance due to costs associated with breast cancer or its treatment?

Question Title

* 13. On a scale of 1 (not important) to 5 (very important), how important are these outcomes for your breast cancer treatment?

  1 - not important 2 3 4 5 - very important
Controlling disease progression
Reducing symptoms
Maintaining quality of life
Managing side effects
Preventing recurrence
Questions 15-31 are for patients with Kisqali treatment experience. If you have not received this treatment, you can proceed directly to Question 32.

Question Title

* 15. Have you been treated as a breast cancer patient with Kisqali (ribociclib)?

Question Title

* 16. Did you receive another endocrine therapy before Kisqali?

Question Title

* 17. Did you receive Kisqali in combination with an aromatase inhibitor like Arimidex (anastrozole), Aromasin (exemestane) or Femara (letrozole)?

Question Title

* 18. Did you receive Kisqali in combination with a luteinizing hormone-releasing hormone (LHRH) agonist like Lupron (leuprolide) or Zoladex (goserelin)?

Question Title

* 19. Please identify any other drugs or therapies that you received as a breast cancer patient either before or after Kisqali.

Question Title

* 20. How long were you treated with Kisqali

Question Title

* 21. Did you require any dose reductions during your treatment with Kisqali?

Question Title

* 22. If you are no longer receiving Kisqali, why?

Question Title

* 23. On a scale of 1 (much worse) to 5 (much better), how has your life changed on Kisqali compared to other therapies that you received?

  1 - much worse 2 3 4 5 - much better
Metastatic cancer symptoms (i.e. bone pain)
Drug side effects
Maintaining quality of life
Controlling disease progression
Ability to work
Ability to sleep
Ability to drive
Ability to perform household chores
Ability to care for children

Question Title

* 24. Which symptoms of metastatic breast cancer has Kisqali helped to manage?

Question Title

* 25. What side effects have you experienced while on Kisqali?

Question Title

* 28. Did you have any difficulty accessing Kisqali?

Question Title

* 29. What alternatives did your doctor suggest if treatment with Kisqali was unavailable?

Question Title

* 30. Did receiving Kisqali as a pill make your treatment experience easier?

Question Title

* 31. Overall, what has been your experience with Kisqali? Describe the positive and negative.

Question Title

* 32. Based on your personal experiences with Kisqali, would you recommend it to other patients with breast cancer?

Question Title

* 33. What country are you from?

Question Title

* 35. Would you be willing to participate in a telephone survey to discuss your experience with Kisqali?

Question Title

* 36. If yes, please enter your email address or phone number below.

If you have a primary caregiver who is willing to participate in this survey, please allow them to complete the following questions by themselves.

If you don't have a primary caregiver or if they do not wish to participate in this survey, click Done at the bottom of the page to complete the survey.

Question Title

* 37. What is your relationship to the breast cancer patient?

Question Title

* 38. How would you describe the severity of the challenges you have faced as a caregiver on a scale of 1 (not at all severe) to 5 (very severe)? Please elaborate in the comments section.

  1 - not at all severe 2 3 4 5 - very severe
Financial
Health
Educational
Social
Professional

Question Title

* 39. What type of support is or would be most helpful for you in order to care for someone with breast cancer?

Question Title

* 40. How did treatment with Kisqali affect your responsibilities as a caregiver?

T